Key Highlights

  • Cumberland Pharmaceuticals (NASDAQ:CPIX) traded at USD 7.18 on November 12, 2026, up 17.32% from an implied prior close of about USD 6.12, on thin Volume of 47,060 shares.
  • Third-quarter results released after the close on November 10 showed Net Income of USD 77.8 million, driven by the gain on the sale of its commercial business.
  • Cash stood at USD 80.6 million on September 30, 2026, a large share of the company's Market Value of about USD 107.58 million on the screen.
  • The company retained its late-stage pipeline, led by ifetroban in Duchenne muscular dystrophy heart disease, which is under rolling review for a new drug application.

The Catalyst: Results Confirm a Cash-Rich Shell With a Pipeline

Cumberland Pharmaceuticals (NASDAQ:CPIX) is a Nashville-based specialty pharmaceutical company that sold its commercial products Business to a generic drug maker in a transaction that closed on July 1, 2026, for USD 100 million at closing plus up to USD 11 million for inventory and transition services. Its third-quarter results, released after the close on November 10 with a call that afternoon, were the first full quarter after the sale. Net income of USD 77.8 million reflected the gain on the transaction. Revenue from continuing operations was about USD 2.16 million against USD 0.17 million a year earlier, and the loss from continuing operations narrowed to about USD 1.12 million from USD 2.73 million. Cash reached USD 80.6 million. Using the screen figures, that cash equals roughly three quarters of the market value, an own calculation that helps explain why buyers stepped in over the following sessions, with the strongest move on November 12.

Ifetroban and the Pipeline Case

The pipeline gives investors a second reason to own the shares. Ifetroban is being developed for cardiomyopathy in Duchenne muscular dystrophy, a fatal muscle-wasting disease in which heart failure is a leading cause of death. In a Phase 2 study the drug produced an absolute improvement of 5.4 points in left ventricular ejection fraction, a measure of how well the heart pumps. In late October the company said regulators granted rolling review of its new drug application, and the stock rose sharply that day. Regulators have, however, suggested a Phase 3 study and raised questions about whether current evidence is sufficient. A separate study in systemic sclerosis did not support an efficacy conclusion, and the shares fell by almost half on that news on October 23. The company also kept a majority stake in its early-stage technology unit, paid a USD 1.50 Special Dividend on July 31 and authorised a buyback of up to USD 5 million.

Fundamentals and Risks

Cumberland Pharmaceuticals (NASDAQ:CPIX) no longer has a commercial product base, so future value depends on Cash Management and the outcome of ifetroban. Trailing diluted Earnings of minus USD 0.73 per share on the screen do not yet reflect the one-off gain in a clean way, and ongoing research costs will consume cash each quarter. Relative volume of only about 0.19 times normal means the 17.32% gain came on light trading, so prices can move sharply on small orders. A request from regulators for another trial would extend timelines and costs. Investors should watch progress on the rolling submission, any further Capital returns, quarterly cash burn and whether the company seeks a partner for ifetroban.

Where Things Stand

Cumberland Pharmaceuticals (NASDAQ:CPIX) rose 17.32% to USD 7.18 on November 12, 2026 as the market digested third-quarter results showing USD 77.8 million of net income from its business sale and USD 80.6 million of cash. Cash covers most of the market value, and ifetroban offers upside if regulators accept the filing. Thin trading, regulatory uncertainty and cash burn are the key risks.